Physician profile
Gokul Narayan Kumar
NPI 1225267867
$9,306.71
in general payments reported to CMS, 2019-2025
27 companies · $2,351 in 2025
The $2,351 reported for 2025 was more than what 90% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,247 · 2020: $743 · 2021: $467 · 2022: $782 · 2023: $1,923 · 2024: $1,794 · 2025: $2,351.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,876 · Travel and Lodging: $193.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,875.53 |
| Travel and Lodging | $192.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $2,159.29 | 2019-2025 | Eylea Hd, Eylea |
| Astellas Pharma US INC | $1,348.56 | 2023-2025 | Izervay |
| Genentech USA, INC. | $963.79 | 2020-2025 | Vabysmo |
| Novartis Pharmaceuticals Corporation | $885.25 | 2019-2021 | |
| Abbvie INC. | $585.97 | 2022-2025 | |
| Apellis Pharmaceuticals, INC. | $488.93 | 2022-2025 | Syfovre |
| Alcon Vision LLC | $440.47 | 2023-2024 | Constellation |
| Alimera Sciences, INC. | $297.73 | 2020-2024 | Yutiq, Iluvien |
| Coherus Oncology, INC. | $284.03 | 2022-2023 | |
| Mallinckrodt Hospital Products INC. | $278.02 | 2022-2025 | Acthar |
| Allergan, INC. | $256.17 | 2019-2021 | |
| Harrow Eye, LLC | $244.94 | 2025 | Iheezo, Triesence |
| Regeneron Pharmaceuticals, INC. | $235.41 | 2020-2023 | Eylea Hd |
| Eyepoint US, INC. | $113.64 | 2020 | |
| Kala Pharmaceuticals, INC. | $109.74 | 2019 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch & Lomb, A Division of Bausch Health US, LLC | $100.00 | 2019 | |
| Sight Sciences, INC. | $90.26 | 2020 | |
| Bausch & Lomb Americas INC. | $85.51 | 2023-2025 | Xipere, Visudyne |
| Dutch Ophthalmic, USA | $71.02 | 2022 | |
| Halozyme INC | $54.84 | 2025 | Hylenex Recombinant |
| Mallinckrodt Enterprises LLC | $47.66 | 2019 | |
| Carl Zeiss Meditec USA, INC. | $40.63 | 2021-2025 | |
| Ani Pharmaceuticals, INC. | $38.19 | 2025 | Iluvien |
| Neurotech Pharmaceuticals, INC. | $28.29 | 2025 | |
| Spark Therapeutics, INC. | $19.80 | 2019 | |
| Carl Zeiss Meditec Ag | $19.40 | 2020 | |
| Biogen, INC. | $19.17 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gokul Kumar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.